Akebia Therapeutics (AKBA) Tops Q1 EPS by 8c

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of $0.03, $0.08 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $57.34 million versus the consensus estimate of $44.38 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• This auto stock is a Top Pick at Citi
• SK Hynix (SKHY) call put ratio 1.1 calls to 1 put as share price up 2.6%